(Q46568123)

English

A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists

scientific article published on 24 June 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15979994

A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15979994

5

object named as

Devroey P

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15979994

author name string

Kolibianakis EM

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15979994

Schultze-Mosgau A

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15979994

Schroer A

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15979994

van Steirteghem A

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15979994

Diedrich K

6

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15979994

Griesinger G

7

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15979994

language of work or name

0 references

publication date

24 June 2005

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15979994

Human Reproduction

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15979994

20

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15979994

10

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15979994

2887-2892

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15979994

The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI150

21 January 2018

Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertil

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI150

21 January 2018

A randomized, assessor-blind, group-comparative efficacy study to compare the effects of Normegon and Metrodin in infertile female patients undergoing in-vitro fertilization.

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI150

21 January 2018

Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization.

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI150

21 January 2018

Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI150

21 January 2018

Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI150

21 January 2018

GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI150

21 January 2018

Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI150

21 January 2018

Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up.

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI150

21 January 2018

Abnormal endometrial development occurs during the luteal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists.

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI150

21 January 2018

Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF.

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI150

21 January 2018

Experience with the elective transfer of two embryos under the conditions of the german embryo protection law: results of a retrospective data analysis of 2573 transfer cycles

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI150

21 January 2018

Luteal phase support in infertility treatment: a meta-analysis of the randomized trials

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI150

21 January 2018

Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI150

21 January 2018

Endometrial evaluation by aspiration biopsy on the day of oocyte retrieval in the embryo transfer cycles in patients with serum progesterone rise during the follicular phase

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI150

21 January 2018

Identifiers

10.1093/HUMREP/DEI150

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15979994

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15979994

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46568123&oldid=2118535101"